On September 23, 2013, LabStyle Innovations Corp. (OTCQB:DRIO) announced the receipt of CE Mark approval to market the Dario smartphone-based diabetes management system in 32 countries across Europe as well as in certain other countries worldwide. The initial roll-out of the Dario device will take place in countries where management has signed distribution partners. This includes launching the device in The U.K., and Belgium under the company's exclusive distribution agreement with Farla Medical, Inc. in Italy under an exclusive distribution agreement with Harmonium Pharma, and in New Zealand with recent distribution partner, InnoMed Ltd.
Management expects these launches to take place, along with a soft roll-out in New Zealand and Australia, in the first...
Only subscribers can access this article, which is part of the PRO research library covering 3,625 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: